Beyond Cancer, Ltd., a clinical stage biotechnology company developing ultra-high concentration nitric oxide (UNO) as an immunotherapeutic for solid tumors and subsidiary of Beyond Air, Inc. (NASDAQ: ...
Repairon’s groundbreaking regenerative heart failure therapy is being evaluated in a Phase 2 clinical study in Germany. As reported recently, an interim analysis presented at the 2025 Scientific ...
Pulsed-field ablation, transcatheter heart valves, and IVL are among the top stories, as they drive growth among the largest ...
Learn about market failure in economics, where supply and demand imbalances lead to inefficient distribution, its types, and ...
SEOUL, South Korea, Jan. 21, 2026 /PRNewswire/ -- FutureMain, a South Korea–based industrial AI and asset transformation (AX) company specializing in predictive maintenance, announced that it is ...
Indian Space Research Organisation (ISRO)’s yet another failure in launching 16 satellites, including one that is strategically important for the country, has raised serious questions. This is the ...
Hosted on MSN
Insmed halts CRSsNP program after Phase 2b failure
The latest announcement is out from Insmed ( (INSM)). On December 17, 2025, Insmed announced the Phase 2b BiRCh study of brensocatib for chronic rhinosinusitis without nasal polyps (CRSsNP) did not ...
Researchers have made a major advance in quantum computing with a new device that is nearly 100 times smaller than the diameter of a human hair. Published in the journal Nature Communications, the ...
An FDA advisory panel declined to endorse the Ventura interatrial shunt system, a heart failure device developed by V-Wave, a Johnson & Johnson company, according to a Dec. 5 TCTMD report. Panel ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results